EGFR and hepatocellular carcinoma: Finally, lipoplexes targeted with anti-EGFR antibodies have been formulated to deliver siRNA to non-small cell lung cancer cell lines28 and into EGFR-overexpressing hepatocellular carcinoma.29 Surface modification was necessary for specific uptake of the siRNA into the cells and resulted in enhanced tumor accumulation when compared to untargeted lipoplexes.